Werewolf Therapeutics, Inc. (HOWL)

Market Cap	259.41M
Revenue (ttm)	16.22M
Net Income (ttm)	-41.58M
Shares Out	42.74M
EPS (ttm)	-1.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138,921
Open	6.13
Previous Close	6.08
Day's Range	5.78 - 6.34
52-Week Range	1.57 - 8.19
Beta	0.71
Analysts	Strong Buy
Price Target	10.86 (+78.91%)
Earnings Date	May 3, 2024

About HOWL

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2021
• Employees: 47
• Stock Exchange: NASDAQ
• Ticker Symbol: HOWL

Financial Performance

In 2023, HOWL's revenue was $19.94 million, an increase of 21.60% compared to the previous year's $16.40 million. Losses were -$37.37 million, -30.56% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for HOWL stock is "Strong Buy." The 12-month stock price forecast is $10.86, which is an increase of 78.91% from the latest price.

Price Target

$10.86

(78.91% upside)

Analyst Consensus: Strong Buy